WR 33063 (3-bromo-10-[a-hydroxy-(s-(n,n-diheptylamino)ethyll-phenanthrene hydrochloride) and WR 30090 (6,8-dichloro-2,3,4-dichlorphenyl-di-n-butylaminoethyl-4-quinolinemethanol The compounds WR 33063 (3-bromo-10-[ahydroxy -,B -(n, n -diheptylamino)ethyl] -phenanthrene hydrochloride) and WR 30090 (6,8-dichloro -2,3,4 -dichlorphenyl -di -n -butyl -aminoethyl-4-quinolinemethanol hydrochloride) were tested in nonimmune volunteers for suppressive prophylactic activity against chloroquine-and pyrimethamine-resistant Plaksnodium falciparum. WR 30090 was also examined for its suppressive action upon P. vivax in man. Human tolerance to these compounds and their therapeutic effect in clinical falciparum and vivax malaria have been described (1, 5) .
WR 33063 (3-bromo-10-[a-hydroxy-(s-(n,n-diheptylamino)ethyll-phenanthrene hydrochloride) and WR 30090 (6,8-dichloro-2,3,4-dichlorphenyl-di-n-butylaminoethyl-4-quinolinemethanol hydrochloride) were tested for suppressive prophylactic effect on induced malaria in nonimmune volunteers living in an area where malaria is not naturally transmitted. Doses of 800 mg of WR 33063 and 690 or 460 mg of WR 30090 were given at weekly intervals to men exposed on the day of the first dose to mosquitoes heavily infected with chloroquine-and pyrimethamine-resistant strains of Plasnodium faliparum. WR 33063 did not interfere with early development of infection, but WR 30090 given for 8 weeks provided suppressive cures in 20 of 26 men. P. vivax infections similarly induced broke through WR 30090 treatment in 4 of 15 men, and most of the remainder experienced malaria after completion of the prophylactic course. No side effects of treatment were observed.
The compounds WR 33063 (3-bromo-10-[ahydroxy -,B -(n, n -diheptylamino)ethyl] -phenanthrene hydrochloride) and WR 30090 (6,8-dichloro -2,3,4 -dichlorphenyl -di -n -butyl -aminoethyl-4-quinolinemethanol hydrochloride) were tested in nonimmune volunteers for suppressive prophylactic activity against chloroquine-and pyrimethamine-resistant Plaksnodium falciparum. WR 30090 was also examined for its suppressive action upon P. vivax in man. Human tolerance to these compounds and their therapeutic effect in clinical falciparum and vivax malaria have been described (1, 5) .
MATERIALS AND METHODS
Transmissions were accomplished by use of colonized Anopheles stephensi. Each volunteer was exposed to 10 or more heavily infected mosquitoes. The interrupted feeding method was not used, the controls being untreated volunteers exposed on each occasion to mosquitoes from the same batch as those used on the men receiving WR 33063 or WR 30090. The parasites used were the Chesson and Vietnam strains of P. vivax and the Philippines (Per), Malaya (Tay), and Vietnam (Smith) strains of P. falciparum. All three of the latter are resistant to chloroquine and pyrimethamine; the Smith strain is also resistant to to chlorguanide (proguanil) , and the Smith strain aind to a lesser extent the Tay strain have diminished susceptibilities to quinine (2 Table 1 ). The untreated controls for the Per and Tay strain exposures developed malaria in 10 and 15 days, respectively. Volunteers were exposed to the Smith strain in two groups, and untreated controls developed malaria in 8 and 11 days. No side effects were attributable to the treatments, which were usually continued for 8 weeks after the infective challenge or (four men) the second of two challenges.
The method for assay of serum levels of WR 30090 was developed too late for use in the first eight cases listed in Table 1 , but was used for the remainder. Levels in specimens collected 24 hr after treatment were uniformly low, ranging from 0.05 to 0.35 ,g/ml, so that from the third weekly dose onwards 8-hr slpecimens were analyzed.
These showed a wide range in WR 30090 content, from 0.00 ug/ml on one occasion (following the fifth dose given to RF; the dose was repeated 2 days later, the only instance that this was done in the study) to 2.25 ,Ag/ml, although all volunteers had swallowed the drugs under careful supervision and stated that they did not vomit subsequently.
Suppression and suppressive cures were obtained in 14 of the 18 men listed ini Table 1 . In one patient, KW, parasitemia developed after completion of the prophylactic course, and in three patients it broke through during an early stage in the course. In these three patients, parasite densities increased so rapidly that alternative treatment was required. The 24-hr drug concentrations in their sera were as follows: EH, 0.15 and 0.05 ,ug/ml; DJ, 0.15 and 0.23 ,ug/ml; and RM, 0.10 and 0.25 ,g/ml.
WR 30090 (460 mg) as a falciparum suppressive. WR 30090 in doses of 460 mg was similarly administered to eight volunteers exposed to mosquitoes heavily infected with the Smith strain ( Table 2 ). The untreated control case developed falciparum malaria after a prepatent period of 8 days. No side effects of treatment were observed.
Suppression and suppressive cures were obtained in six of the eight men. In two patients, infection broke through early in the prophylactic course and developed rapidly, making it necessary for other types of treatment to be instituted. The Suppressive cure a The initials of each volunteer are followed by his age (in years), his race (C = Caucasian; N = Negro), and his weight (in kilograms). Volunteers HC and WHu were exposed to the Per strain, WHa and RQ were exposed to the Tay strain, and the remainder were exposed to the Smith strain. Tables 1 and 2 as having been challenged 7 days previously with P. falciparum. The results of the vivax prophylactic trial are shown in Table 3 and may be summarized as follows. vThe initials of each volunteer are followed by his age (in years), his race (C = Caucasian; N = Negro), and his weight (in kilograms). Volunteers WB, DO, HT, TE, and LH were exposed to the Vietnam strain; the remainder were exposed to the Chesson strain.
b Concentrations of WR 30090 are the means of specimens collected 8 hr after the weekly treatments. For the 24-hr levels of CS, RW, AM, and JM, see text.
ACTIVITY OF WR 33063 AND WR 30090 IN MALARIA 223
Among the nine men given 690 mg of WR 30090, infection broke through the weekly treatment in two and developed after completion of the course in some others listed in Table 3 . Concentrations of WR 30090 in serum with this dosage ranged from 0.10 to 0.37 ug/ml for 24-hr specimens and from 0.10 to 2.55 jug/ml for 8-hr specimens. The 24-hr levels in the two patients who developed early infections were as follows: CS, 0.25 and 0.25 ,ug/ml; and RW, 0.37 and 0.10 jsg/ml.
Six men were given 460 mg of WR 30090. Breakthrough occurred in two, and parasitemia appeared upon completion of the course in some others listed in Table 3 . Drug concentrations in serum ranged from 0.10 to 0.35 ;g/ml for 24-hr specimens and 0.10 to 1.20 ug/ml for those collected after 8 hr. The 24-hr levels in the patients showing early breakthrough were 0.10 and 0.15 jsg/ml for AM and 0.23 and 0.35 jug/ml for JM.
DISCUSSION
Although WR 33063 given to nonimmune volunteers at weekly intervals did not suppress P. falciparum, WR 30090 was more successful. When the latter compound was administered for 8 weeks, commencing at the time of exposure of volunteers to mosquitoes heavily infected with chloroquine-and pyrimethamine-resistant parasites, suppression and suppressive cure occurred in 14 of 18 men receiving 690 mg and in 6 of 8 men receiving 460 mg. Concentrations of WR 30090 tended to be lower in the serum of those men sustaining infection, but this was not a consistent finding. In view of the rapid diminution of WR 30090 in serum, the amount 24 hr after ingestion of 690 or 460 mg often approaching the lowest observable level, it was somewhat surprising that parasite suppression was usually achieved with weekly treatments.
The dosage of 690 mg of WR 30090, given daily for 6 days, had proved effective in the treatment of most cases of malaria caused by similar strains of P. falciparum (5) . To determine whether the parasites breaking through our prophylactic use of the drug had developed resistance to it, the infections developing in volunteers EH (Table 1) and LJ (Table 2) were treated with the 6-day course of WR 30090. Radical cure occurred in both cases.
This protection by WR 30090 of 75 to 78% of the volunteers exposed to P. falciparum was achieved without apparent side effects. It may be compared with the results obtained when we used DFD (diformyl diaminodiphenyl sulfone; WR 6798) with chloroquine or pyrimethamine under identical conditions; 93% of volunteers were protected from these strains (Clyde et al., Mil. Med., in pre88).
As a prophylactic of P. vivax, WR 30090 was less effective. Infection broke through during the course of the weekly treatment in two of nine men receiving the 690-mg dose and in two of six receiving 460 mg, whereas the use of chloroquine alone (3, 4) , or of DFD with chloroquine or p.yrimethamine (Clyde et al., in pre88) , ensured suppression while treatment was in progress. Upon completion of treatment with WR 30090, 6 of the 11 men who had hitherto escaped parasitemia developed it. After courses of chloroquine alone or with DFD, vivax infections are known to develop regularly, whereas this does not appear to occur after DFD with pyrimethamine (3, 4; Clyde et al., in pre88).
